ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,849.20
-0.41%
S&P ASX All Technology
3,086.40
-0.75%
Brent Oil
83.14
-0.08%
US Dollar vs AUD
1.49807
0.09%
Bitcoin
65,483.28
0.37%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) News

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GILD
DateTimeSourceHeadlineSymbolCompany
15/05/202400:09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
10/05/202407:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202406:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
10/05/202406:05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
10/05/202405:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202405:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
09/05/202406:58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
07/05/202422:30Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024NASDAQ:GILDGilead Sciences Inc
01/05/202406:05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
26/04/202422:00Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
26/04/202421:47IH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
26/04/202406:02Business WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
25/04/202421:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
09/04/202406:05Business WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
28/03/202423:30Business WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
28/03/202422:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
28/03/202422:00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
23/03/202400:18Business WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:GILDGilead Sciences Inc
19/03/202410:29Business WireCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantNASDAQ:GILDGilead Sciences Inc
11/03/202423:34Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:GILDGilead Sciences Inc
11/03/202423:24Business WireGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferNASDAQ:GILDGilead Sciences Inc
07/03/202408:30Business WireBiktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesNASDAQ:GILDGilead Sciences Inc
07/03/202402:25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NASDAQ:GILDGilead Sciences Inc
07/03/202400:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:GILDGilead Sciences Inc
06/03/202408:35Business WireNew Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19NASDAQ:GILDGilead Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:GILD

Your Recent History

LSE
18KU
Arab Rep.egp 48
BIT
I08070
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved